Employer Coverage Gaps Are Pushing Patients Toward the Cash-Pay Telehealth Weight Loss Program

More than half of American adults who have taken a GLP-1 medication say it was difficult to afford. In KFF’s May 2024 Health Tracking Poll, 54 percent of adults who had ever used these drugs reported difficulty paying for them, including 22 percent who described it as “very difficult.” Among insured adults who had taken them, only 24 percent said their insurance covered the full cost, and 19 percent said they had paid the entire cost out of pocket.

Those findings capture a tension at the heart of modern weight care. Demand for GLP-1 treatment has surged, but coverage through employer health plans, where most working-age Americans get their insurance, remains inconsistent and heavily dependent on the size of the employer. Into that gap has stepped a fast-growing cash-pay market, with the telehealth weight loss program emerging as one of its most common formats.

A market defined by uneven coverage

KFF’s poll found that 12 percent of U.S. adults had ever used a GLP-1 drug and 6 percent were currently using one at the time of the survey. That translates into millions of people navigating a benefit that their employers may or may not provide.

Firm size determines access

KFF’s 2025 Employer Health Benefits Survey shows how sharply coverage varies by employer size. Among firms offering health benefits, 43 percent of those with 5,000 or more workers covered GLP-1 medications for weight loss in 2025, up from 28 percent a year earlier. Coverage fell steeply at smaller sizes: 30 percent of firms with 1,000 to 4,999 workers and just 16 percent of firms with 200 to 999 workers reported covering the drugs for weight loss.

The implication is significant. A worker’s access to employer-funded weight treatment depends less on clinical need than on where they happen to work. Employees at large corporations are increasingly likely to have some coverage; employees at mid-sized companies are far less likely to.

Premiums are rising regardless

Even where coverage is absent, workers are paying more for insurance. The same KFF survey found that the average annual premium for employer-sponsored family coverage reached $26,993 in 2025, a 6 percent increase over 2024. Covered workers contributed an average of $6,850 toward that family premium, or about 26 percent of the total. For many households, paying more each year for a plan that still excludes weight-management medication is a key reason to look elsewhere.

Why employers hesitate

Employer reluctance is rooted in cost and uncertainty. GLP-1 medications are expensive at list prices, the population of potentially eligible employees is large, and treatment for a chronic condition can continue for an extended period. For a self-insured employer, adding coverage can mean a meaningful and difficult-to-forecast increase in pharmacy spending.

Common approaches to limiting exposure

Employers that do cover GLP-1 medications for weight management often attach conditions designed to manage costs. These can include:

• Prior authorization: requiring documentation of BMI and related conditions before approving a prescription.
• Program participation: requiring enrollment in a lifestyle or coaching program alongside medication.
• Utilization management: limiting which medications are on formulary or how long coverage lasts.
• Carve-outs: covering the drugs for diabetes but not for weight management.

Each of these measures can be reasonable from a plan-design standpoint, but each also adds friction for the patient. Paperwork, waiting periods and denials are common reasons people abandon the insurance route entirely.

The rise of cash-pay care

When coverage is missing or difficult to use, a growing share of patients are choosing to pay directly. Cash-pay care has long existed in areas such as dermatology, fertility and elective procedures, but weight management has become one of its largest new frontiers.

What cash-pay patients value

Patients who pay out of pocket tend to prioritize predictability. A transparent monthly price, no prior-authorization process and the ability to start quickly can outweigh the appeal of insurance coverage that may or may not come through. Telehealth fits naturally into that preference: intake, clinician review and follow-up can be completed remotely, and medication can be shipped to the patient’s home.

Tax-advantaged accounts fill part of the gap

Health savings accounts and flexible spending accounts give many workers a way to use pre-tax dollars for qualifying medical expenses, which can soften the cost of cash-pay care. For employees whose plans exclude weight-management medication, these accounts have become an important bridge between employer benefits and out-of-pocket spending. Installment payment options have also become more common in direct-to-consumer health, giving patients additional flexibility in how they budget for care.

Who ends up paying cash

The cash-pay population is more varied than it may first appear. It includes employees of mid-sized companies whose plans exclude weight-management medication, self-employed workers and gig workers buying coverage on their own, and people whose insurance technically covers GLP-1 drugs but whose prior-authorization requests were denied. It also includes patients who would rather not route a weight-related prescription through an employer-sponsored plan at all, whether for privacy or simplicity.

KFF’s polling hints at the scale of that group. With 19 percent of insured users reporting that they paid the entire cost themselves, a meaningful share of people who technically have insurance are already behaving like cash-pay patients. For them, the relevant comparison is not insured versus uninsured care, but which out-of-pocket option offers the most predictable price and the least administrative friction.

The role of telehealth infrastructure

Telehealth has made the cash-pay model practical at a national scale. Online intake, remote clinician review and mail-order pharmacy fulfillment allow a single program to serve patients in many states without a network of physical clinics. That efficiency helps explain why so much of the cash-pay weight-care market has developed online rather than in traditional offices.

How it works in practice

HealSend, a LegitScript-verified U.S. telehealth pharmacy, is one example of how a cash-pay telehealth weight loss program is structured. Patients complete a quick online health profile, and a clinician reviews the intake. HealSend states that every patient is reviewed by a U.S.-licensed physician before any prescription and that eligibility for GLP-1 medications is determined by a licensed physician. The program is open to adults aged 18 to 75 and is not for use during pregnancy.

The company lists compounded semaglutide at $299 per month and compounded tirzepatide at $399 per month, each as a once-weekly injection, with free shipping via FedEx in discreet, temperature-controlled packaging. Compounded medications are prepared by a licensed pharmacy for an individual patient; they are not approved by the FDA and do not go through its premarket review for safety, effectiveness or quality. HealSend states that its weight-care plans are FSA and HSA eligible for reimbursement, and that if its provider determines a GLP-1 medication is not right for a patient, the patient receives a full refund. Service is available across most U.S. states, with some states excluded, and every prescription remains contingent on a licensed clinician’s assessment.

Friction points and what comes next

Large employers are moving, smaller ones are not

The jump in coverage among the largest employers, from 28 percent to 43 percent in a single year according to KFF, shows that attitudes can change quickly when workforce demand is strong. Whether that shift reaches smaller employers is the key open question. Firms with 200 to 999 workers have less negotiating power and less capacity to absorb cost volatility, so the coverage gap by employer size may persist for some time.

Affordability remains the central concern

KFF’s finding that more than half of users found GLP-1 treatment difficult to afford is a reminder that cash-pay care does not solve affordability on its own. It changes who pays and how, but the cost still lands on households. Transparent pricing, tax-advantaged accounts and flexible payment terms help, but they do not eliminate the burden for lower-income patients.

Continuity across coverage changes

Because obesity is a chronic condition, patients may move between covered and cash-pay care as they change jobs or as employer policies shift. That churn creates a risk of interrupted treatment. Care models that keep medical records, clinician relationships and follow-up consistent regardless of how a patient is paying are likely to become more valuable as the market matures.

Oversight and verification

The growth of cash-pay weight care has also attracted operators of varying quality. Third-party pharmacy verification, state-by-state licensing of prescribers and clear clinical eligibility screening are becoming important signals for patients trying to distinguish legitimate medical programs from unregulated sellers.

Conclusion

The data from KFF tell a consistent story. Demand for GLP-1 treatment is real and widespread, affordability is a challenge for most people who use it, and employer coverage depends heavily on company size. Large employers are expanding coverage quickly, while mid-sized firms lag far behind, and family premiums continue to rise regardless.

In that environment, the growth of cash-pay telehealth is less a disruption than a predictable response to a coverage system that has not kept pace with clinical practice. Its long-term role will depend on how employer benefits evolve. If coverage broadens across firm sizes, cash-pay care may become one option among many; if gaps persist, it is likely to remain a primary route to treatment for millions of working Americans.